Anzeige
Mehr »
Lynx Broker
Login
Donnerstag, 17.10.2019 Börsentäglich über 12.000 News von 613 internationalen Medien
Konkurrenz beeindruckt! Bisher noch unentdeckt von Investoren ist die neue Technologie jetzt marktreif! Aktie vor Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XA8R ISIN: DK0060534915 Ticker-Symbol: NOVC 
Tradegate
16.10.19
21:22 Uhr
47,200 Euro
-0,485
-1,02 %
1-Jahres-Chart
NOVO NORDISK A/S Chart 1 Jahr
5-Tage-Chart
NOVO NORDISK A/S 5-Tage-Chart
RealtimeGeldBriefZeit
47,245
47,470
16.10.
47,245
47,370
16.10.
24.04.2019 | 18:29
(87 Leser)
(0 Bewertungen)

Bagsværd, Denmark, 24 April 2019 - At Novo Nordisk's Annual General Meeting on 21 March 2019, it was decided to reduce the company's B share capital from DKK 382,512,800 to DKK 372,512,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company's share capital is nominally DKK 480,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 372,512,800.

The reduction of the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.

Further information

Media:
Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com (mailto:amhg@novonordisk.com)
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com (mailto:kiau@novonordisk.com)
Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com (mailto:phak@novonordisk.com)
Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com (mailto:jvls@novonordisk.com)
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com (mailto:arnd@novonordisk.com)
Kristoffer Due Berg (US) +1 609 235 2989 krdb@novonordisk.com (mailto:krdb@novonordisk.com)


Company announcement no. 24 / 2019


20190424 - Capital Reduction (http://hugin.info/2013/R/2242468/885002.pdf)



This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire


© 2019 GlobeNewswire (Europe)